87 related articles for article (PubMed ID: 18535575)
1. Wandering eye for RNAi.
Rossi J; Zamore P; Kay MA
Nat Med; 2008 Jun; 14(6):611. PubMed ID: 18535575
[No Abstract] [Full Text] [Related]
2. RNA interference: generic block on angiogenesis.
Kalluri R; Kanasaki K
Nature; 2008 Apr; 452(7187):543-5. PubMed ID: 18385725
[No Abstract] [Full Text] [Related]
3. [Unspecific effects of certain siRNA molecules used in the treatment of age related macular degeneration].
Ebbesen M; Bek T; Pedersen FS; Jensen TG
Ugeskr Laeger; 2010 Sep; 172(36):2457-9. PubMed ID: 20825735
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy using the small interfering RNA bevasiranib.
Singerman L
Retina; 2009 Jun; 29(6 Suppl):S49-50. PubMed ID: 19553802
[TBL] [Abstract][Full Text] [Related]
5. Silence is golden: can RNA interference therapeutics deliver?
Beal J
Drug Discov Today; 2005 Feb; 10(3):169-72. PubMed ID: 15708529
[No Abstract] [Full Text] [Related]
6. RNAi and tumor angiogenesis: bridging the gap towards anti-cancer therapy?
Dave RS
Leuk Res; 2007 Apr; 31(4):421-2. PubMed ID: 17157908
[No Abstract] [Full Text] [Related]
7. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
[TBL] [Abstract][Full Text] [Related]
8. [Application of functional RNAs in human diseases].
Tanaka Y; Kozu T
Tanpakushitsu Kakusan Koso; 2006 Nov; 51(14 Suppl):2235-7. PubMed ID: 17471945
[No Abstract] [Full Text] [Related]
9. A crucial test.
Check E
Nat Med; 2005 Mar; 11(3):243-4. PubMed ID: 15746929
[No Abstract] [Full Text] [Related]
10. Suppression of retinal neovascularization by shRNA targeting HIF-1alpha.
Xia XB; Xiong SQ; Xu HZ; Jiang J; Li Y
Curr Eye Res; 2008 Oct; 33(10):892-902. PubMed ID: 18853324
[TBL] [Abstract][Full Text] [Related]
11. Regeneron focuses on age-related macular degeneration.
Wolfson W
Chem Biol; 2008 Apr; 15(4):303-4. PubMed ID: 18420133
[No Abstract] [Full Text] [Related]
12. Genetics. First gene for severe dry macular degeneration.
Kaiser J
Science; 2008 Aug; 321(5893):1146-7. PubMed ID: 18755949
[No Abstract] [Full Text] [Related]
13. [VEGF, anti-vEGF and diseases].
Corvol P
Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
[TBL] [Abstract][Full Text] [Related]
14. Age-related macular degeneration.
Brucker AJ
Retina; 2009 Jun; 29(6 Suppl):S2-4. PubMed ID: 19553791
[TBL] [Abstract][Full Text] [Related]
15. VEGF inhibition: insights from preclinical and clinical studies.
Crawford Y; Ferrara N
Cell Tissue Res; 2009 Jan; 335(1):261-9. PubMed ID: 18766380
[TBL] [Abstract][Full Text] [Related]
16. Strategies for inhibiting vascular endothelial growth factor.
Kaiser PK
Retina; 2009 Jun; 29(6 Suppl):S15-7. PubMed ID: 19553789
[TBL] [Abstract][Full Text] [Related]
17. Pathology beyond neovascularization: new targets in age-related macular degeneration.
Heier JS
Retina; 2009 Jun; 29(6 Suppl):S39-41. PubMed ID: 19553799
[TBL] [Abstract][Full Text] [Related]
18. Aflibercept (eylea) for age-related macular degeneration.
Med Lett Drugs Ther; 2012 Feb; 54(1383):9-10. PubMed ID: 22354219
[No Abstract] [Full Text] [Related]
19. Anti-Vascular Endothelial Growth Factor Injection for Exudative Age-related Macular Degeneration in Patients with Vitreo-Macular Traction.
Querques G
Am J Ophthalmol; 2009 Feb; 147(2):375-6; author reply 376-7. PubMed ID: 19166716
[No Abstract] [Full Text] [Related]
20. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
Busch T
Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
